A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker bisoprolol (Zebeta) in patients with atrial ...
Researchers in atrial fibrillation (AF) focus mostly on paroxysmal and persistent AF. Permanent AF is largely ignored. The reason is obvious: nonpermanent forms of AF may be treated with ablation.
Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback